Literature DB >> 27532447

Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations.

J Wouter Jukema1, Maddalena Lettino2, Petr Widimský3, Nicolas Danchin4, Alfredo Bardaji5, Jose A Barrabes6, Angel Cequier7, Marc J Claeys8, Leonardo De Luca9, Jakob Dörler10, David Erlinge11, Paul Erne12, Patrick Goldstein13, Sasha M Koul11, Gilles Lemesle14, Thomas F Lüscher15, Christian M Matter16, Gilles Montalescot17, Dragana Radovanovic18, Jose Lopez-Sendón19, Petr Tousek3, Franz Weidinger20, Clive F M Weston21, Azfar Zaman22, Uwe Zeymer23.   

Abstract

Patient registries that document real-world clinical experience play an important role in cardiology as they complement the data from randomized controlled trials, provide valuable information on drug use and clinical outcomes, and evaluate to what extent guidelines are followed in practice. The Platelet Inhibition Registry in ACS EvalUation Study (PIRAEUS) project is an initiative of registry holders who are managing national or international registries observing patients with acute coronary syndromes (ACS). The aim of PIRAEUS is to systematically compare and combine available information/insights from various European ACS registries with a focus on P2Y12 inhibitors. The present publication introduces the 17 participating registries in a narrative and tabular form, and describes which ACS groups and which dual antiplatelet therapies were investigated. It sets the basis for upcoming publications that will focus on effectiveness and safety of the antiplatelets used. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Acute coronary syndrome; Antithrombotics; Clopidogrel; Methodology; Non-ST-segment myocardial infarction; Observational; P2Y12 inhibitors; Prasugrel; Real-world evidence; Registries; ST-segment elevation myocardial infarction; Ticagrelor

Mesh:

Substances:

Year:  2015        PMID: 27532447     DOI: 10.1093/ehjcvp/pvv024

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Pharmacother


  4 in total

1.  Patient characteristics, treatment strategy, outcomes, and hospital costs of acute coronary syndrome: 3 years of data from a large high-volume centre in Central Europe.

Authors:  Petr Toušek; David Bauer; Marek Neuberg; Markéta Nováčková; Petr Mašek; Petr Tu Ma; Viktor Kočka; Zuzana Moťovská; Petr Widimský
Journal:  Eur Heart J Suppl       Date:  2022-03-30       Impact factor: 1.624

2.  High adherence to therapy and low cardiac mortality and morbidity in patients after acute coronary syndrome systematically managed by office-based cardiologists in Germany: 1-year outcomes of the ProAcor Study.

Authors:  Franz Goss; Johannes Brachmann; Christian W Hamm; Winfried Haerer; Nicolaus Reifart; Benny Levenson
Journal:  Vasc Health Risk Manag       Date:  2017-04-06

Review 3.  The Role of Clopidogrel in 2020: A Reappraisal.

Authors:  Giuseppe Patti; Giuseppe Micieli; Claudio Cimminiello; Leonardo Bolognese
Journal:  Cardiovasc Ther       Date:  2020-03-16       Impact factor: 3.023

4.  Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries.

Authors:  Leonardo De Luca; Uwe Zeymer; Marc J Claeys; Jakob Dörler; Paul Erne; Christian M Matter; Dragana Radovanovic; Franz Weidinger; Thomas F Lüscher; Johan Wouter Jukema
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2021-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.